• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.470 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,528
Open 3.470
Bid (Size) 3.470 (2,400)
Ask (Size) 3.490 (3,500)
Prev. Close 3.470
Today's Range 3.470 - 3.470
52wk Range 1.639 - 5.630
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
March 12, 2026
Via MarketBeat

Performance

YTD
+37.7%
+37.7%
1 Month
-35.9%
-35.9%
3 Month
+25.3%
+25.3%
6 Month
+52.9%
+52.9%
1 Year
+21.8%
+21.8%

More News

Read More
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
March 05, 2026
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
March 05, 2026
Via Stocktwits
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
February 24, 2026
Via Chartmill
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
February 25, 2026
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
February 24, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
February 24, 2026
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
February 24, 2026
Via The Motley Fool
Topics Earnings
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
February 24, 2026
Via Stocktwits
News headline image
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗
February 23, 2026
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
February 11, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
February 05, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
IOVA Shares Jump 8% — What’s Retail Expecting? ↗
January 26, 2026
Via Stocktwits
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 16, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
December 30, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
December 29, 2025
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 19, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
December 07, 2025
Via The Motley Fool
News headline image
Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 3.470
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 1.06B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap